The aim of the study was to systematically explore the relationships between various
adipokines and risks of endometrial atypical
hyperplasia (EAH), type I
endometrial cancer (EC), and type II EC. We enrolled 219 patients in this study, including 39 EAH, 87 type I EC, 38 type II EC and 55 control individuals. We subsequently explored the association of
adipokine levels and the
leptin-to-
adiponectin (L/A) ratio with EAH, type I EC, and type II EC. The plasma
leptin level and L/A ratio were significantly higher in the EAH group than in the control group (p = 0.012).
Leptin,
resistin, vaspin, and
visfatin levels were significantly higher in the type I EC group; however, the
adiponectin level was lower in the type I EC, which resulted in a higher L/A ratio. Notably, the L/A ratio and
visfatin level in the type II EC group were significantly higher. Multiple logistic regression analysis revealed that a higher
leptin level was significantly associated with a higher EAH risk (p = 0.012). Higher
leptin level (p = 0.042) and L/A ratio (p = 0.027) were significantly associated with an increased type I EC risk. By contrast, higher
leptin (p = 0.059) and
visfatin (p = 0.003) levels, higher L/A ratio (p = 0.033), and lower
adiponectin level (p = 0.042) were associated with an increased type II EC risk. We suggested that
adipokines are potentially correlated with EAH and EC risks.